Medical treatment for heavy menstrual bleeding
Journal
Taiwanese Journal of Obstetrics and Gynecology
Journal Volume
54
Journal Issue
5
Pages
483-488
Date Issued
2015
Author(s)
Chen Y.-J
Li Y.-T
Huang B.-S
Yen M.-S
Wang P.-H
Chen C.-H
Chao H.-T
Wen K.-C
Ho C.-H
Tsai H.-W
Chang Y.-H
Chang Y.-W
Chen C.-Y
Horng H.-C
Hung M.-J
Tsui K.-H
Liu J.-Y
Yu M.-H
Chen T.-H
Chu T.-Y
Lin W.-C
Hung Y.-C
Sun H.-D
Wu W.-Y
Hsiao S.-M
Wang Y.-L
Chen T.-C
Huang J.-P
Hung J.-H
Chen K.-H
Lee F.-K
Lai T.-H
Chen C.-H
Wu M.-H
Wang C.-J
Wang T.-H
Chang T.-C
Hsieh C.-H
Seow K.-M
Taiwan Association of Gynecology Systematic Review Group
Abstract
Heavy menstrual bleeding, or menorrhagia, is subjectively defined as a "complaint of a large amount of bleeding during menstrual cycles that occurs over several consecutive cycles" and is objectively defined as menstrual blood loss of more than 80 mL per cycle that is associated with an anemia status (defined as a hemoglobin level of <10 g/dL). During their reproductive age, more than 30% of women will complain of or experience a heavy amount of bleeding, which leads to a debilitating health outcome, including significantly reduced health-related quality of life, and a considerable economic burden on the health care system. Although surgical treatment might be the most important definite treatment, especially hysterectomy for those women who have finished bearing children, the uterus is still regarded as the regulator and controller of important physiological functions, a sexual organ, a source of energy and vitality, and a maintainer of youth and attractiveness. This has resulted in a modern trend in which women may reconsider the possibility of organ preservation. For women who wish to retain the uterus, medical treatment may be one of the best alternatives. In this review, recent trends in the management of women with heavy menstrual bleeding are discussed. ? 2015.
SDGs
Other Subjects
antibiotic agent; asoprisnil; danazol; gestagen; gestrinone; gonadorelin agonist; hemoglobin; leuprorelin; levonorgestrel; lonaprisan; medroxyprogesterone; megestrol; mifepristone; nonsteroid antiinflammatory agent; onapristone; oral contraceptive agent; pra 910; progesterone receptor modulator; telapristone acetate; tranexamic acid; ulipristal; unclassified drug; antifibrinolytic agent; adenomyoma; artificial embolism; classification algorithm; conservative treatment; drug cost; endometrium atrophy; endometrium cancer; endometrium hyperplasia; hemoglobin blood level; hereditary nonpolyposis colorectal cancer; hormonal therapy; human; hysterectomy; leiomyoma; levonorgestrel releasing intrauterine system; long term care; menorrhagia; menstruation; ovary insufficiency; patient counseling; quality of life; Review; transvaginal echography; uterus; female; hemostatic technique; menorrhagia; pregnancy; procedures; severity of illness index; treatment outcome; Antifibrinolytic Agents; Female; Hemostatic Techniques; Humans; Hysterectomy; Menorrhagia; Pregnancy; Severity of Illness Index; Treatment Outcome
Type
review